• Sulforaphane Workflows for Stress and Inflammation

  2026-08-23

  Translate Sulforaphane biology into reproducible cell, macrophage, and mouse workflows spanning oxidative stress, inflammasome signaling, and cancer chemoprevention. The article emphasizes dose selection, orthogonal readouts, and troubleshooting strategies that distinguish pathway modulation from nonspecific toxicity.

• GSK3 Inhibition Controls Mycobacterium tuberculosis

  2026-08-22

  The reference study identifies glycogen synthase kinase 3 as a host pathway that supports intracellular Mycobacterium tuberculosis growth and validates this target through pharmacological, CRISPR, RNAi, and phospho-proteomic approaches. Its findings strengthen the rationale for host-directed tuberculosis therapy, while also defining important mechanistic and translational limits for moving from macrophage models to treatment strategies.

• 2-NBDG Maps Glycolytic Uptake in Glioblastoma

  2026-08-21

  Learn how 2-NBDG can distinguish glucose transport and retention from downstream glycolytic activity in glioblastoma. This mechanistic guide connects fluorescent uptake measurements with recent PXDN–LDHA findings and practical assay design.

• JZL184 in Pain Research: Assay Design

  2026-08-20

  JZL184 is a selective monoacylglycerol lipase inhibitor for dissecting 2-AG biology, CB1 signaling, and pain-related behavior. This guide develops an assay-centered framework that connects endocannabinoid signaling modulation with sensory, affective, biochemical, and circuit-level readouts.

• 20-HETE–TRPV1 Signaling in Chronic Dermatitis

  2026-08-20

  The reference study identifies elevated 20-HETE as a peripheral lipid signal that activates sensitized TRPV1 channels on MrgprA3+ sensory neurons, causing pain-inducing stimuli to produce itch-like scratching in chronic dermatitis. Its combination of sensory-neuron manipulation, electrophysiology, metabolomics, and pharmacological inhibition provides a mechanistic framework for studying allokinesis and potential itch interventions.

• Podophyllotoxin: From Mitotic Arrest to MDR Strategy

  2026-08-19

  A translational analysis of Podophyllotoxin biology, multidrug-resistance research, assay design, formulation strategy, and the boundaries between a mechanistic research reagent and clinical product concepts.

• DGLA–ACSL4 Ferroptosis in AML Cells

  2026-08-19

  The reference study identifies dihomo-γ-linolenic acid (DGLA) as a lipid-metabolic trigger of ferroptosis in acute myeloid leukemia (AML) cells and places ACSL4 at the center of this response. Its combination of targeted metabolomics, fatty-acid testing, ACSL4 knockout, and in vivo dietary intervention provides a mechanistic framework for exploiting ferroptosis in treatment-resistant leukemia.

• ω-Agatoxin IVA TFA: Cav2.1 Workflow Guide

  2026-08-18

  ω-Agatoxin IVA TFA enables selective interrogation of Cav2.1-dependent calcium entry, synaptic release, and seizure-related phenotypes. This practical guide connects nanomolar electrophysiology with structure-aware assay design, epilepsy animal model planning, and troubleshooting.

• Metformin Hydrochloride: AMPK and HO Research

  2026-08-18

  Metformin Hydrochloride, also called Metformin HCl, is a widely studied metabolic regulator that suppresses hepatic gluconeogenesis without directly stimulating insulin secretion. Research models connect its AMPK, mitochondrial redox, lipid-regulatory, and Nr4a1/Wnt/β-catenin effects to glucose homeostasis and experimental heterotopic ossification biology.

• Anisomycin Workflows for JNK and Apoptosis

  2026-08-17

  Anisomycin is a practical JNK agonist for time-resolved apoptosis assays across cancer and stress-response models. This guide combines solvent-aware handling, quantitative signaling workflows, and a cautious neuroscience extension inspired by recent neuroligin 1 research.

• NF 449 for P2X1 Platelet Studies

  2026-08-17

  NF 449 combines strong recombinant P2X1 potency with a practical workflow for separating ATP-driven signaling from broader platelet P2-receptor effects. Use it to refine platelet activation studies, collagen-induced platelet aggregation assays, and translational antithrombotic agent research without treating a single concentration as universally selective.

• MK-5108 (VX-689): AURKA Assay Strategy

  2026-08-16

  MK-5108 (VX-689) is a highly selective Aurora A inhibitor for connecting kinase biochemistry with cell-cycle and retinoblastoma research. This guide explains how AURKA biology, assay design, and xenograft evidence should shape experimental interpretation.

• Nadolol (SQ-11725): PK Workflows for Beta Blockade

  2026-08-15

  Nadolol (SQ-11725) combines reproducible non-selective beta-adrenergic blockade with transporter-aware pharmacokinetic questions. This practical guide shows how to design cardiovascular assays, interpret OATP1A2-related disposition, and adapt disease-state PK lessons without overextending evidence from a MASH model.

• Cy3 RNA Labeling Kit: HyperScribe™ T7

  2026-08-14

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus supports in vitro transcription of randomly Cy3-modified RNA probes for fluorescence-based research workflows. It is intended for applications such as in situ hybridization and Northern blotting, but it is not for diagnostic, therapeutic, or medical use.

• T7 RNA Polymerase for Translational RNA Workflows

  2026-08-14

  T7 RNA Polymerase converts promoter-bearing DNA into research-grade RNA for vaccine design, antisense studies, RNAi, and functional assays. This guide connects template engineering and reaction optimization with the comparative mRNA vaccine findings reported for varicella-zoster virus glycoprotein E.

7869 records 1/525 page Next 12345 下5页 Last page